Member Info for inanaco

BioNtech have an Option ... if they don't take it up, then they lose the research, its not a case that Biontech can mess around to suit. Its signed

Mia that is the problem everyone is discussing what has not been said .. rather than sitting back patiently and waiting for what will be said ..
I still think its working out how to separate the patients CD4 T cells into phenotype before infecting with the Viral TCR then cloning ....... that is the only difference with CD8 which BioNtech i assume has experience of .. But its only a guess

why would Diggles after doing Due Diligence within the organisation support TCR ? ....... you take what is not said and extrapolate a meaning when you have no idea how the contract with BioNtech is structured ... Scancells lips may be sealed

BioNtech is a Private company anyway ... so any NDA between them is strictly ND

They are recruiting ? all the UK systems are Go .. ie... New Ichor Guns in place, training on them completed .. etc

Code 1

We are about to treat the first patient ......... on keytruda with SCIB1

obviously that first patient is NOT treated by Scancell .. we don't have a clinic ...

so any date given has to be flexible as its "patient and Oncologist" not the stock market deadline

you don't have the bank balance to test that Ruck ...

the important thing is very little liquidity without sellers, so any good news, it may be difficult to buy ... primed again for a movement up ...

500,000 ................... shares

if after treatment from Braf, the cancer returns its even more aggressive .. that is the problem

trouble is it could get dire ...........

This is the largest series of unselected patients treated in real-life with anti-PD-1 as second-or-higher line of treatment. Anti-PD-1 was less effective in BRAF-mutated cases as a majority of patients presented aggressive tumor evolution after BRAFi discontinuation. These data are consistent with previous studies suggesting a negative impact of BRAFi prior to immunotherapy.

https://bmccancer.biomedcentral.com/articles/10.1186/s12885-018-4618-9

C7 .. don't get me wrong I have passion ... but i am backing that passion for the science as an investment because the science stacks up ...

hence i did not Buy VAL >>>

Its puts an alarm on Scancell shares ...

Tick Tock

just watched it ... impressive

C7 fully aware of cancer ... which is why i highlight Rucks post the other day pointing out "all" cancer is Dire if you have not responded, but when investing you have to separate the "Moral ground" which has its own investment sector "Charities"

Scancell is a PLC not a charity as such the market requirement is for treatments that can meet an unmet need ..but behind that is fiscal prudence .. which is why rare cancers do not attract the funding like the majors, but this is the Crossover point of the charities getting involved . CRUK thou run a mix of Investment and charity funding ...

CRUK scientist are in constant research and indeed license out discovery for commercial money to invest.

and as we have seen are prepared to back great science SCIB2 over there own discoveries ... !!!

the issue as ever is time ..........

Low affinity Binding ...

high avidity binding ...

Scancell significant skills are being able to built the best Mabs for """"Binding""""

indeed Immunbody is a Mab ...

now you can appreciate the crossover between

Immunobody and Clycans

should have explained that a bit better ... the "sugar" on the cancer cell is a binding target ...

which its why its a Cylcan Mab .. in other words the Mab is binding to the Sugar epitopes of which many exist

so the potential MAB is a protein binding to a Sugar ...

its what the Mab does ... which is what is important ...

this is the separation point between BioNtech and Scancell ... lewis A

about lewis A ... etc .. Scancell has our Mabs patented i assume BioNtech has its Mabs patented only there is a lot of them

https://link.springer.com/chapter/10.1007/978-1-4419-7877-6_4

so if you look at the original release RNS about Glycans

We believe this platform complements our existing ImmunoBody® and Moditope® platforms, significantly broadening the strength and potential of Scancell's immunotherapy pipeline."

now you can see why Lindy has shown great interest ... and its the way our Glycans Bind ...